Inhibition of acetylcholine synthesis and of carbohydrate utilization by maple-syrup-urine disease metabolites.
D000109:Acetylcholine / Q000096:biosynthesis*; D000596:Amino Acids / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002417:Cattle; D005947:Glucose / Q000378:metabolism*; D006019:Glycolysis / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D007651:Keto Acids / Q000494:pharmacology*; D007655:Ketoglutarate Dehydrogenase Complex / Q000378:metabolism; D007668:Kidney / Q000201:enzymology; D007700:Kinetics; D008375:Maple Syrup Urine Disease / Q000503:physiopathology*; D011768:Pyruvate Dehydrogenase Complex / Q000378:metabolism; D011770:Pyruvate Kinase / Q000378:metabolism; D011773:Pyruvates / Q000378:metabolism*; D051381:Rats
D000596:Amino Acids; D007651:Keto Acids; D011768:Pyruvate Dehydrogenase Complex; D011773:Pyruvates; D007655:Ketoglutarate Dehydrogenase Complex; D011770:Pyruvate Kinase; D005947:Glucose; D000109:Acetylcholine